Lilly to pay up to $335 million for testosterone solution
16 March 2010
Simon Varcoe
simon.varcoe@informa.com
Lilly is to pay Acrux $50 million up front for the global commercialisation rights to its underarm testosterone solution Axiron.
The Australian company will also receive $3 million in the transfer of manufacturing assets and could receive $87 million on the receipt of US FDA marketing authorisation,...
Please Login to read the full article.